Ignite Creation Date:
2024-05-06 @ 7:32 PM
Last Modification Date:
2024-10-26 @ 3:08 PM
Study NCT ID:
NCT06047080
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2023-09-14
Brief Title:
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin Rituximab Cyclophosphamide Doxorubicin and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
A Phase III Multicenter Randomized Open-Label Study Comparing the Efficacy and Safety of Glofitamab RO7082859 in Combination With Polatuzumab Vedotin Plus Rituximab Cyclophosphamide Doxorubicin and Prednisone Pola-R-CHP Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab cyclophosphamide doxorubicin and prednisone Pola-R-CHP vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma LBCL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None